EFEITOS SECUNDÁRIOS CUTÂNEOS DA TERAPÊUTICA HIPOGLICEMIANTE | CUTANEOUS SIDE EFFECTS OF DIABETES TREATMENT
Resumo
RESUMO
As lesões cutâneas são frequentes na diabetes mellitus, havendo um envolvimento da pele em cerca de 30 a 91% dos
doentes durante o curso da doença. Estas podem ser não infeciosas ou autoimunes, infeciosas ou resultar de complicações
do tratamento da diabetes, pelo uso de insulina ou outros antidiabéticos.
O crescente aumento na prevalência da diabetes mellitus tipo 2 e o advento, na última década, de novos antidiabéticos
orais e injetáveis com diferentes mecanismos celulares de atuação, justificam não só uma adequada orientação técnica sobre
a sequência de introdução de cada classe terapêutica, como o reconhecimento dos seus efeitos laterais, nomeadamente even-
tuais reações cutâneas adversas. A resolução destas dermatoses passa pela substituição farmacológica ou pelo aumento da
rotatividade do local onde se administra a insulina.
Os autores apresentam uma revisão da abordagem terapêutica da diabetes mellitus tipo 2, dando especial destaque às
possíveis reações cutâneas adversas aos hipoglicemiantes que hoje em dia temos ao nosso dispor.
A pesquisa bibliográfica foi realizada através de ferramentas eletrónicas de pesquisa avançada e não avançada das seguintes
fontes de dados: PubMed e Cochrane Library. Os artigos citados foram considerados os mais relevantes.
Palavras-chave: Antidiabéticos; Diabetes mellitus; Dermatoses medicamentosas
ABSTRACT
Skin lesions are common in diabetes mellitus, with approximately 30 to 91% of the patients experiencing at least one dermatologic com-
plication during the course of their illness. These can be non-infectious or autoimmune manifestations, cutaneous infections or related to
diabetic treatment by the use of insulin or other antidiabetic drugs.
The crescent increase of prevalence of type 2 diabetes mellitus and the emergence, in the last decade, of new oral and injectable drugs
with different cellular mechanisms, not only implies an adequate guidance on the introdution sequence of each drug class but also the ackno-
wledgment of their side effects, including adverse cutaneous reactions. These disorders usually resolve by switching treatment or by rotating
the injection site of insulin.
The authors present a review of the therapeutic management of type 2 diabetes with a special emphasis to the adverse cutaneous reactions
caused by antidiabetic drugs.
A bibliographic review of relevant and recent papers was performed using advanced electronic research tools and not advanced the fol-
lowing data sources: PubMed and Cochrane Library.
Keywords: Antidiabetic drugs; Diabetes mellitus; Drug eruptions
Texto Completo:
PDFReferências
Ahmed I, Goldstein B. Diabetes mellitus. Clin Dermatol. 2006;24(4):237-246.
IDF Diabetes Atlas - 2014 Update. Vol 6th editio. International Diabetes Federation; 2014. [consultado 2015 abr 28]. Disponível em: www.idf.org/diabetesatlas.
Correia LG. Diabetes : Factos & Números 2014 - Relatório Anual do Observatório Nacional da Diabetes. Lisboa; 2014.
Demirseren DD, Emre S, Akoglu G, et al. Relationship Between Skin Diseases and Extracutaneous Complications of Diabetes Mellitus: Clinical Analysis of 750
Patients. Am J Clin Dermatol. 2014;15:65-70.
Levy L, Zeichner JA. Dermatologic manifestation of diabetes. J Diabetes. 2012;4:68-76.
American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2015;38:S9-S11.
Murphy-Chutorian B, Han G, Cohen SR. Dermatologic Manifestations of Diabetes Mellitus: A Review. Endocrinol Metab Clin North Am. 2013;42:869-898.
Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
Diabetes Obes Metab. 2011;13:221-228.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
Glucophage (metformin) Full Prescribing Information. Bristol Myers Scquibb; 2009. [consultado 2015 maio 2]. Disponível em: http://packageinserts.bms.com/pi/
pi_glucophage_xr.pdf.
Koca R, Altinyazar HC, Yenidunya S, Tekin NS. Psoriasiform drug eruption associated with metformin hydrochloride: A case report. Dermatol Online J. 2013;19:1-19.
Azzam H, R B, Friedman-Birnbaum R. Lichen planus Associated with Metformin Therapy. Dermatology. 1997;194:376.
Czarnowicki T, Ramot Y, Ingber A, Maly A, Horev L. Metformin-Induced Leukocytoclastic Vasculitis: A Case Report. Am J Clin Dermatol. 2012;13:61-63.
Klapholz L, Leitersdorf E, Weinrauch L. Leucocytoclastic vasculitis and pneumonitis induced by metformin. Br Med J. 1986;293:483.
Ben Salem C, Hmouda H, Slim R, Denguezli M, Belajouza C, Bouraoui K. Rare case of metformin-induced leukocytoclastic vasculitis. Ann Pharmacother.
;40:1685-1687.
Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatology Venereol. 2013;27:1329-1335.
Schwartz A V, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349-3354.
Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes
Care. 2011;34:1369-1371.
Actos (pioglitazone) Full Prescribing Information. Takeda Pharmaceuticals America; 1999. [consultado 2015 maio 2]. Disponível em: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2011/021073s043s044lbl.pdf.
Taylor SR, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy.
;33:984-999.
FORXIGA (dapagliflozin) Full Prescription Information.; 2014. [consultado 2015 maio 27]. Disponível em: http://www.accessdata.fda.gov/drugsatfda_docs/
label/2014/202293s003lbl.pdf.
Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes
Complications. 2013;27:479-484.
Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187-215.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet.
;368:1696-1705.
Bunck MC, Diamant M, Eliasson B, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care.
;33:1734-1737.
Nathan DM, Buse JB, Davidson MB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy:
A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational,
open-label trial (LEAD-6). Lancet. 2009;374:39-47.
Victoza (liraglutide) Full Prescription Information. Novo Nordisk; 2010. [consultado 2015 maio 21]. Disponível em: https://www.accessdata.fda.gov/drugsatfda_
docs/label/2010/022341lbl.pdf.
Byetta Safety Update for Healthcare Professionals. [consultado 2015 maio 21]. Disponível em: http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm.
Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
Besemer F, Verschoor AJ, Diamant M, Hoogma RPLM. Vesiculopustular dermatosis: An uncommon side-effect of liraglutide? J Diabetes Complications. 2012;26:458-459.
Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on
glycemic response or increased frequency of adverse events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab.
;96:1695-1702.
Makdissi A, Ghanim H, Vora M, et al. Sitagliptin Exerts an Antinflammatory Action. Jounal Clin Endocrinol Metab. 2012;97:3333-3341.
Onglyza (saxagliptin) Full Prescribing Information. AstraZeneca Pharmaceuticals; 2009. [consultado 2015 maio 25]. Disponível em: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2009/022350lbl.pdf.
Galvus (vildagliptin) Full Prescription Information. Novartis; 2010. [consultado 2015 maio 25]. Disponível em: http://www.novartis.com.au/PI_PDF/gal.pdf.
Januvia (sitagliptin) Full Prescription Information. Merck Sharp & Dohme; 2006. [consultado 2015 maio 25]. Disponível em: http://www.merck.com/product/usa/
pi_circulars/j/januvia/januvia_pi.pdf.
Nakatani K, Kurose T, Hyo T, et al. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus
metformin. Diabetes Ther. 2012;3:1-5.
Desai S, Brinker A, Swann J, Iyasu S. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med. 2010;170:1169-1171.
Gupta M, Gupta A. Fixed drug eruption to sitagliptin. J Diabetes Metab Disord. 2015;14:2-4.
Stricklin SM, Stoecker W V., Rader RK, Hood AF, Litt JZ, Schuman TP. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
Dermatol Online J. 2012;18:15-17.
Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: Report of two cases.
Diabetes Care. 2011;34:2011.
Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV
inhibitors plus metformin. J Eur Acad Dermatology Venereol. 2012;26:249-253.
Aouidad I, Fite C, Marinho E, Deschamps L, Crickx B, Descamps V. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA
dermatology. 2013;149:243-245.
Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J
Dermatol Case Rep. 2014;8:24-28.
Béné J, Jacobsoone A, Coupe P, et al. Bullous pemphigoid induced by vildagliptin: a report of three cases. Fundam Clin Pharmacol. 2015;29:112-114.
Apontamentos
- Não há apontamentos.